The prevention of dementia with antihypertensive treatment: New evidence from the systolic hypertension in Europe (syst-eur) study

Archives of Internal Medicine

Volumn 162, Issue 18, 2002, Pages 2046-2052

  Forette, Françoise ^a   Seux, Marie Laure ^a   Staessen, Jan A ^b   Thijs, Lutgarde ^b   Babarskiene, Marija Ruta ^c   Babeanu, Speranta ^d   Bossini, Alfredo ^e   Fagard, Robert ^b   Gil Extremera, Blas ^f   Laks, Tovio ^g   Kobalava, Zhanna ^h   Sarti, Cinzia ^i,j   Tuomilehto, Jaakko ^i,j   Vanhanen, Hannu ^j   Webster, John ^k   Yodfat, Yair ^l   Birkenhäger, Willem H ^m  

^a Paris Descartes University   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^d Gerontology and Geriatrics   (Romania)

^e POLICLINICO UMBERTO I   (Italy)

^f UNIVERSITY OF GRANADA   (Spain)

^g Tallinn Central Hospital   (Estonia)

^h Moscow Clinical Hospital   (Russian Federation)

ⁱ NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^j UNIVERSITY OF HELSINKI   (Finland)

^k UNIVERSITY OF ABERDEEN   (United Kingdom)

^l HEBREW UNIVERSITY   (Israel)

^m ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIHYDROPYRIDINE; ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE; NITRENDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG USE; EUROPE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 0037078312     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.18.2046     Document Type: Article

References (54)

1. Rigaud AS, Seux ML, Staessen JA, Birkenhäger WH, Forette F. Cerebral complications of hypertension. J Hum Hypertens. 2000;14:605-616.
2. Birkenhäger WH, Forette F, Seux ML, Wang JG, Staessen JA. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med. 2001;161:152-156.
3. Fratiglioni L, De Ronchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999;15:365-375.
4. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
5. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357:373-380.
6. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
7. Gasowski J, Staessen JA, Celis H, et al. Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol and initial progress. J Hum Hypertens. 1999;13:135-145.
8. Forette F, Amery A, Staessen J, et al. Is prevention of vascular dementia possible? the Syst-Eur Vascular Dementia Project. Aging Clin Exp Res. 1991;3:373-382.
9. Amery A, Birkenhäger W, Bulpitt CJ, et al. Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging Clin Exp Res. 1991;3:287-302.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
11. Gagnon M, Letenneur L, Dartigues JF, et al. The validity of the Mini-Mental State Examination as a screening instrument for cognitive impairment and dementia in French elderly community residents. Neuroepidemiology. 1990;3:143-150.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
13. Launer LJ. Overview of incidence studies of dementia conducted in Europe. Neuroepidemiology. 1992;11(suppl 1):2-13.
14. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401.
15. Hachinski VC, Lliff LD, Zilkha E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
16. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. JAMA. 1963;185:914-919.
17. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997; 349:151-154.
18. Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study. BMJ. 1994; 308:1604-1608.
19. Launer LJ, Webster Ross G, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:49-55.
20. Prince M, Cullen M, Mann A. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology. 1994;44:97-104.
21. Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000;21:153-160.
22. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol. 1997;244:135-142.
23. Skoog I, Marcusson J, Blennow K. It's getting better all the time. Lancet. 1998; 352(suppl 4):SIV4.
24. Hachinski V. Vascular dementia: the need for a new approach. J intern Med. 1997; 242:277-279.
25. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. Neurology. 1999;53:1992-1997.
26. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med. 1993;328:153-158.
27. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MB. Incidence of dementia: does gender make a difference? Neurobiol Aging. 2001;22:575-580.
28. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship with medication use. Arch Neurol. 1999;56:991-996.
29. Tzourio C, Dufouil C, Ducimetière P, Alpérovitch A, for the EVA Study Group. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. Neurology. 1999;53:1948-1952.
30. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22:407-412.
31. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
32. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ. 1996; 312:801-805.
33. Staessen JA, Gasowski J, Wang JG, etal. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000; 355:865-872.
34. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
35. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
36. PROGRESS Management Committee. PROGRESS-Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens. 1999;17:1647-1655.
37. Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol. 2001;153:72-78.
38. Morich FJ, Bieber F, Lewis JM, et al. Nimodipine in the treatment of probable Alzheimer's disease: result of two multicentre trials. Clin Drug Invest. 1996;11: 185-195.
39. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs. 1997;53:752-768.
40. Mason RP, Leeds PR, Jacob RF, et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem. 1999;72:1448-1456.
41. Amenta F, Strocchi P, Sabbatini M. Vascular and neuronal hypertensive brain damage: protective effect of treatment with nicardipine. J Hypertens. 1996;14 (suppl 3):S29-S36.
42. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med. 1999;341:1543-1544.
43. Pascale A, Etcheberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res. 1999;39:81-88.
44. Thibault O, Porter NM, Chen KC. Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. Cell Calcium. 1998;25:417-433.
45. Hong YL. The relationship between calcium antagonist-induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol. 1987;11:589-597.
46. Murzenok PP, Huang BS, Leenen FHH. Sympathoinhibition by central and peripheral infusion of nifedipine in spontaneously hypertensive rats. Hypertension. 2000;35:631-636.
47. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rat brain with [3H]nitrendipine. Brain Res. 1985; 330:217-223.
48. Letenneur L, Commenges RD, Dartigues JF, Barberger-Gateau P. Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int J Epidemiol. 1994;23:1256-1261.
49. Ott A, Breteler MMB, van Harskamp F, Grobbee DE, Hofman A. The incidence of dementia in the Rotterdam study. In: Iqbal K, Winblad B, Nishimura T, Takeda K, Winieski H, eds. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. New York, NY: John Wiley & Sons; 1997:1-10.
50. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;355: 1955-1964.
51. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-1315.
52. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.
53. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies. Lancet. 2000;356:1949-1954.
54. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999;161:501-506.